- Home
- GNFT vs INZY Comparison
GNFT vs INZY Comparison
Compare GNFT & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- INZY
- Stock Information
- Founded
- GNFT 1999
- INZY 2015
- Country
- GNFT France
- INZY United States
- Employees
- GNFT N/A
- INZY N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- INZY Health Care
- Exchange
- GNFT Nasdaq
- INZY Nasdaq
- Market Cap
- GNFT 172.2M
- INZY 188.2M
- IPO Year
- GNFT 2019
- INZY 2020
- Fundamental
- Price
- GNFT $3.47
- INZY $1.36
- Analyst Decision
- GNFT Strong Buy
- INZY Strong Buy
- Analyst Count
- GNFT 1
- INZY 8
- Target Price
- GNFT $13.00
- INZY $17.75
- AVG Volume (30 Days)
- GNFT 6.9K
- INZY 784.0K
- Earning Date
- GNFT 09-19-2024
- INZY 03-11-2025
- Dividend Yield
- GNFT N/A
- INZY N/A
- EPS Growth
- GNFT N/A
- INZY N/A
- EPS
- GNFT 0.47
- INZY N/A
- Revenue
- GNFT $86,225,222.00
- INZY N/A
- Revenue This Year
- GNFT $145.20
- INZY N/A
- Revenue Next Year
- GNFT N/A
- INZY N/A
- P/E Ratio
- GNFT $7.56
- INZY N/A
- Revenue Growth
- GNFT 175.45
- INZY N/A
- 52 Week Low
- GNFT $3.33
- INZY $1.32
- 52 Week High
- GNFT $6.42
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- GNFT 31.89
- INZY 20.27
- Support Level
- GNFT $3.35
- INZY $1.32
- Resistance Level
- GNFT $3.57
- INZY $3.18
- Average True Range (ATR)
- GNFT 0.11
- INZY 0.27
- MACD
- GNFT 0.01
- INZY -0.15
- Stochastic Oscillator
- GNFT 21.82
- INZY 2.15
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.